These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22491045)

  • 21. Assessment of target dose delivery in anal cancer using in vivo thermoluminescent dosimetry.
    Weber DC; Nouet P; Kurtz JM; Allal AS
    Radiother Oncol; 2001 Apr; 59(1):39-43. PubMed ID: 11295204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PET/CT in anal cancer - is it worth doing?
    Wells IT; Fox BM
    Clin Radiol; 2012 Jun; 67(6):535-40. PubMed ID: 22208962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post burn Marjolin's ulcer in the natal cleft mimicking anal canal carcinoma: a rare site.
    Jain SK; Tanwar R; Kaza RC; Ghuliani D
    J Wound Care; 2010 Dec; 19(12):532-4. PubMed ID: 21160444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.
    Tempero MA; Arnoletti JP; Behrman SW; Ben-Josef E; Benson AB; Casper ES; Cohen SJ; Czito B; Ellenhorn JD; Hawkins WG; Herman J; Hoffman JP; Ko A; Komanduri S; Koong A; Ma WW; Malafa MP; Merchant NB; Mulvihill SJ; Muscarella P; Nakakura EK; Obando J; Pitman MB; Sasson AR; Tally A; Thayer SP; Whiting S; Wolff RA; Wolpin BM; Freedman-Cass DA; Shead DA;
    J Natl Compr Canc Netw; 2012 Jun; 10(6):703-13. PubMed ID: 22679115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MR staging of anal cancer: what the radiologist needs to know.
    Golia Pernicka JS; Sheedy SP; Ernst RD; Minsky BD; Ganeshan D; Rauch GM
    Abdom Radiol (NY); 2019 Nov; 44(11):3726-3739. PubMed ID: 31041496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer.
    Ng M; Leong T; Chander S; Chu J; Kneebone A; Carroll S; Wiltshire K; Ngan S; Kachnic L
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1455-62. PubMed ID: 22401917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomography.
    Rusten E; Rekstad BL; Undseth C; Al-Haidari G; Hanekamp B; Hernes E; Hellebust TP; Malinen E; Guren MG
    Radiat Oncol; 2017 Sep; 12(1):147. PubMed ID: 28874205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review.
    Piperkova E; Raphael B; Altinyay M; Castellon I; Libes R; Sandella N; Abdel-Dayem H
    J BUON; 2006; 11(4):523-7. PubMed ID: 17309188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDG-PET/CT in the evaluation of anal carcinoma.
    Cotter SE; Grigsby PW; Siegel BA; Dehdashti F; Malyapa RS; Fleshman JW; Birnbaum EH; Wang X; Abbey E; Tan B; Kodner IJ; Hunt SR; Lowney JK; Mutch MG; Dietz DW; Myerson RJ
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):720-5. PubMed ID: 16626889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.
    Mohler JL; Armstrong AJ; Bahnson RR; Boston B; Busby JE; D'Amico AV; Eastham JA; Enke CA; Farrington T; Higano CS; Horwitz EM; Kantoff PW; Kawachi MH; Kuettel M; Lee RJ; MacVicar GR; Malcolm AW; Miller D; Plimack ER; Pow-Sang JM; Roach M; Rohren E; Rosenfeld S; Srinivas S; Strope SA; Tward J; Twardowski P; Walsh PC; Ho M; Shead DA
    J Natl Compr Canc Netw; 2012 Sep; 10(9):1081-7. PubMed ID: 22956807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PET-CT fusion in radiation management of patients with anorectal tumors.
    Anderson C; Koshy M; Staley C; Esiashvili N; Ghavidel S; Fowler Z; Fox T; Esteves F; Landry J; Godette K
    Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):155-62. PubMed ID: 17707268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines.
    Wood DE; Kazerooni E; Baum SL; Dransfield MT; Eapen GA; Ettinger DS; Hou L; Jackman DM; Klippenstein D; Kumar R; Lackner RP; Leard LE; Leung AN; Makani SS; Massion PP; Meyers BF; Otterson GA; Peairs K; Pipavath S; Pratt-Pozo C; Reddy C; Reid ME; Rotter AJ; Sachs PB; Schabath MB; Sequist LV; Tong BC; Travis WD; Yang SC; Gregory KM; Hughes M;
    J Natl Compr Canc Netw; 2015 Jan; 13(1):23-34; quiz 34. PubMed ID: 25583767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
    Grabenbauer GG; Kessler H; Matzel KE; Sauer R; Hohenberger W; Schneider IH
    Dis Colon Rectum; 2005 Sep; 48(9):1742-51. PubMed ID: 15991058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does an erroneous diagnosis of squamous-cell carcinoma of the anal canal and anal margin at first physician visit influence prognosis?
    Jensen SL; Hagen K; Shokouh-Amiri MH; Nielsen OV
    Dis Colon Rectum; 1987 May; 30(5):345-51. PubMed ID: 3568924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of ¹⁸fluoro-deoxy glucose combined position emission and computed tomography in the clinical management of anal squamous cell carcinoma.
    Engledow AH; Skipworth JR; Blackman G; Groves A; Bomanji J; Warren SJ; Ell PJ; Boulos PB
    Colorectal Dis; 2011 May; 13(5):532-7. PubMed ID: 20070338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
    Zimmermann M; Beer J; Bodis S; von Moos R; Vlachopoulou V; Zwahlen DR; Oehler C
    Acta Oncol; 2017 Dec; 56(12):1734-1740. PubMed ID: 28557585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Squamous cell carcinoma of the anal canal showing complete response following chemoradiotherapy--a case report].
    Tajima Y; Ishibashi K; Gonda T; Miyazaki T; Nakada H; Takahashi T; Ishida H
    Gan To Kagaku Ryoho; 2007 Nov; 34(12):2050-2. PubMed ID: 18219895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer.
    Gauthé M; Richard-Molard M; Fayard J; Alberini JL; Cacheux W; Lièvre A
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):63-70. PubMed ID: 27503193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients.
    Touboul E; Schlienger M; Buffat L; Lefkopoulos D; Pène F; Parc R; Tiret E; Gallot D; Malafosse M; Laugier A
    Cancer; 1994 Mar; 73(6):1569-79. PubMed ID: 8156483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival.
    Mohammadkhani Shali S; Schmitt V; Behrendt FF; Winz OH; Heinzel A; Mottaghy FM; Eble MJ; Verburg FA
    Eur J Radiol; 2016 Aug; 85(8):1390-4. PubMed ID: 27423677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.